Slagle Amanda K, Ghiringhelli Borsa Nicolo, Wang Kai, Taylor Amanda O, Meyer Nicole C, Jones Michael B, Walls William D, Nelson Angela F M, Roberts Sarah M, Sun Mingyao, Goicoechea de Jorge Elena, Rodriguez de Cordoba Santiago, Jalal Diana I, Nester Carla M, Zhang Yuzhou, Smith Richard J H
Molecular Otolaryngology and Renal Research Laboratories, Carver College of Medicine, University of Iowa, Iowa, IA, United States.
Graduate PhD Program in Immunology, Carver College of Medicine, University of Iowa, Iowa, IA, United States.
Front Immunol. 2025 May 16;16:1589674. doi: 10.3389/fimmu.2025.1589674. eCollection 2025.
Dysregulation of the alternative pathway of complement underlies the pathogenesis of C3 glomerulopathy (C3G). Because Factor H (FH) prevents excessive alternative pathway activity while Factor H-related protein 1 (FHR-1) is believed to enhance this response, we investigated the balance between FH and FHR-1 in C3G.
To assess the role of FHR-1 in C3G pathogenicity, we used a multiplex ligation-dependent probe amplification to detect copy number variants in and enzyme linked immunosorbent assays to measure circulating protein levels in C3G patients compared to controls. Additionally, an C3b deposition assay was used to characterize the functional impact of FHR-1 on local complement activity.
In this study, we confirm that copy number impacts C3G risk. In C3G patients with two copies of , the FHR-1:FH protein ratios are increased compared to controls; however, this increase is not disease specific. Rather, it is reflective of deteriorating renal function and was also observed in a second cohort of patients with chronic kidney disease from a variety of other causes. Functional studies showed that FHR-1 competes with FH to increase C3b deposition on mouse mesangial cell surfaces, an effect enhanced by heparan sulfate cleavage.
Altogether, we show that as renal function declines, a change in the FHR-1:FH ratio combined with changes in heparan sulfate architecture increase complement activity. These findings suggest that complement activity may contribute to the chronic inflammation and progression of renal damage associated with chronic kidney disease.
补体替代途径的失调是C3肾小球病(C3G)发病机制的基础。由于因子H(FH)可防止替代途径过度激活,而相关蛋白1(FHR-1)被认为会增强这种反应,因此我们研究了C3G中FH与FHR-1之间的平衡。
为评估FHR-1在C3G致病性中的作用,我们使用多重连接依赖探针扩增技术检测拷贝数变异,并采用酶联免疫吸附测定法测量C3G患者与对照组的循环蛋白水平。此外,还使用C3b沉积试验来表征FHR-1对局部补体活性的功能影响。
在本研究中,我们证实拷贝数会影响C3G风险。在携带两个拷贝的C3G患者中,与对照组相比,FHR-1:FH蛋白比率升高;然而,这种升高并非疾病特异性的。相反,它反映了肾功能的恶化,在另一组由多种其他原因导致的慢性肾病患者中也观察到了这一现象。功能研究表明,FHR-1与FH竞争,增加C3b在小鼠系膜细胞表面的沉积,硫酸乙酰肝素裂解可增强这一效应。
总之,我们表明随着肾功能下降,FHR-1:FH比率的变化与硫酸乙酰肝素结构的变化共同增加了补体活性。这些发现表明补体活性可能促成了与慢性肾病相关的慢性炎症和肾损伤进展。